ASLAN Pharmaceuticals Ltd - ADR

Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

Is  (ASLN) Outperforming Other Medical Stocks This Year?

Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year?

As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.

Will ASLAN Continue to Surge Higher?

SINGAPORE, Dec.  06, 2019  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the closing of its previously announced underwritten public offering of 5,893,206 American Depositary Shares (“ADSs”) at a public offering price of US$2.50 per ADS, including the exercise in full of the underwriter’s option to purchase additional ADSs. Each ADS represents five ordinary shares of ASLAN. The gross proceeds to ASLAN, before deducting underwriting discounts, commissions and other offering expenses, were approximately US$14.7 million. The aggregate offering amount, including the underwriter’s option, reflects the maximum market value of securities that ASLAN is allowed to sell under “baby shelf” rules currently applicable to its effective shelf registration statement on Form F-3.

ASLAN Pharmaceuticals Announces Closing of US$15 Million Public Offering of American Depositary Shares, Including Full Exercise of Underwriter’s Option to Purchase Additional ADSs

The U.S.-listed shares of Aslan Pharmaceuticals Ltd.  plunged 47% in active afternoon trading on Tuesday, after the Singapore-based biotechnology company's stock offering priced at less than half the previous session's closing price.

Aslan Pharmaceuticals stock plunges after stock offering prices at a 52% discount

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) has been on a roller coaster for the past two weeks.

How Aslan Pharma Is Capitalizing on Its Huge Atopic Dermatitis Success

SINGAPORE, Dec.  03, 2019  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has priced its previously announced underwritten public offering of 5,124,527 American Depositary Shares (“ADSs”) at a public offering price of $2.50 per ADS. Each ADS represents five ordinary shares of ASLAN. The gross proceeds to ASLAN, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $12.8 million. All of the ADSs in the offering are being sold by ASLAN. In addition, ASLAN has granted the underwriter an option, exercisable at any time through and until one day before the closing date of this offering, to purchase up to an additional 768,679 ADSs at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about 5 December 2019, subject to customary closing conditions. The aggregate offering amount, including the underwriter’s option, reflects the maximum market value of securities that ASLAN is allowed to sell under “baby shelf” rules currently applicable to its effective shelf registration statement on Form F-3.

ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares

Shares of Aslan Pharmaceuticals Ltd.  jumped 42% on heavy volume in afternoon trading, but pared by more than half earlier gains of over 100%, after the biotechnology company took advantage of a more-than 12-fold rally in six days to sell more shares to the public.

Aslan stock pares its big gain after announcing stock offering

After soaring 81.25% Wednesday and augmenting the gains by an incremental 65% Friday, ASLAN PHARMACEU/ADR (NASDAQ: ASLN) shares were  accelerating further Monday morning.

Aslan's Rally Grows After Positive Readout From Eczema Drug Study

Shares of Aslan Pharmaceuticals Ltd. soared 77% in active premarket trading Monday, after the Singapore-based biopharmaceutical company revealed positive preliminary data from a proof-of-concept study of its atopic dermatitis treatment ASLAN004.

Aslan Pharmaceuticals' stock soars on heavy volume, after rocketing nearly 9-fold the past week

- ASLAN004 demonstrates early signs of efficacy in the low dose cohort of multiple ascending dose study

ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

SINGAPORE, Nov.  22, 2019  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical data characterising ASLAN003 as a potential treatment for acute myeloid leukaemia (AML) has been published in the November issue of Haematologica Journal. The findings support ASLAN003’s potential as a potent human dihydroorotate dehydrogenase (DHODH) inhibitor and novel target for differentiation therapy with a favourable toxicity profile.

ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal

ASLAN PHARMACEU/ADR (NASDAQ: ASLN) shares are trading at sub-$1 levels following a clinical readout from the company.

Aslan Dips Into Penny Stock Territory After Company Flunks Late-Stage Cancer Study

- The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control arm. These were not significant at the pre-specified levels

ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Strong Buy: Rationale Behind the Upgrade

- Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis

ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

SINGAPORE, Oct.  18, 2019  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3 million loan facility provided by the company’s chairman, members of the board, and several major investors. The loan facility will be used to provide the company with additional working capital to support ongoing research and development programs and clinical studies.

ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility

SINGAPORE, Oct.  02, 2019  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced  the presentation of new data from a phase 1b open-label, dose escalation study of varlitinib in combination with modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) chemotherapy to determine the safety, tolerability and maximum tolerated dose (MTD) in advanced solid tumours. The study findings were presented in a poster session at the 2019 European Society for Medical Oncology (ESMO) Congress.

New Data Presented on ASLAN’s varlitinib at ESMO 2019

- ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million 

ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies

- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8 months

ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

SINGAPORE, Sept.  10, 2019  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on its lead candidate, varlitinib, has been accepted for poster presentation at the ESMO Asia Congress 2019 in Singapore on 22 November – 24 November.

Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019

SINGAPORE, Aug.  27, 2019  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking abstract detailing results from a phase 2 study of varlitinib in patients with advanced or metastatic biliary tract cancer in China has been accepted for oral presentation at the upcoming 2019 Chinese Society of Clinical Oncology (CSCO) in Xiamen, China on 19 September 2019.

News for ASLAN Pharmaceuticals Ltd - ADR Stock (ASLN)